Ποια είναι η τιμή για Algernon Pharmaceuticals Inc. (AGN)

Η τιμή για Algernon Pharmaceuticals Inc. (AGN) είναι $0.29357476

Ποια είναι η κεφαλαιοποίηση αγοράς για Algernon Pharmaceuticals Inc. (AGN)

Η κεφαλαιοποίηση αγοράς για Algernon Pharmaceuticals Inc. (AGN) είναι $1.02M

Algernon Pharmaceuticals Inc. (AGN) Δείκτης P/B

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Έτος	Δείκτης P/B	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

Δείκτης P/B

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	Δείκτης P/B	Διαφορά Δείκτη P/B	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	-	US
Argenx SE ARGX.US	6.3483	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	-	BE

Εταιρεία

Δείκτης P/B

Διαφορά Δείκτη P/B

Χώρα